YONGIN, South Korea , Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its proprietary varicella vaccine strain MAV/06 has been included in the World Health Organization (WHO) Position Paper on varicella vaccination, published on November 21.

WHO Position Paper serves as the most authoritative global guidance for immunization policy, developed by the Strategic Advisory Group of Experts on Immunization (SAGE).

With this inclusion, BARYCELA Inj. — GC Biopharma's varicella vaccine based on the MAV/06 strain — has attained equivalent international recognition to Oka strain-based vaccines. The WHO also endorsed the interchangeability of MAV/06 and Oka strains, allowing BARYCELA Inj. to be vaccinated with existing varicella vaccine

See Full Page